Erika Hamilton shared on LinkedIn:

“Happy to share our publication re: T-DXd vs. T-DM1 among patients with brain metastasis in DB-03.

For patients with BMs, the median (95%CI) PFS was 15.0 (12.5-22.2) months for T-DXd vs 3.0 (95% CI, 2.8-5.8) months for T-DM1.

For patients with BMs, confirmed systemic ORR was 67.4% for T-DXd versus 20.5% for T-DM1. Intracranial ORR was 65.7% with T-DXd versus 34.3% with T-DM1.

Source: Erika Hamilton/LinkedIn

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.

Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.